CMP (Comprehensive Metabolic Panel): Drugs That Distort This Test

What the CMP Actually Measures

The CMP is a 14-analyte blood panel ordered by clinicians to screen kidney function, liver function, electrolyte balance, and acid-base status in a single draw. The FDA-cleared analytes span metabolic chemistry that reflects the work of the kidney, liver, and adrenal-parathyroid axis together.

The 14 Analytes and Their Reference Ranges

Each laboratory sets its own reference intervals, but the ranges below reflect commonly published adult values and are consistent with the National Library of Medicine's MedlinePlus guidance.

| Analyte | Typical Adult Reference Range | |---|---| | Glucose (fasting) | 70 to 99 mg/dL | | BUN (blood urea nitrogen) | 7 to 20 mg/dL | | Creatinine | 0.74 to 1.35 mg/dL (male); 0.59 to 1.04 mg/dL (female) | | eGFR | >60 mL/min/1.73 m² | | Sodium | 136 to 145 mEq/L | | Potassium | 3.5 to 5.1 mEq/L | | Chloride | 98 to 107 mEq/L | | CO2 (bicarbonate) | 22 to 29 mEq/L | | Calcium | 8.5 to 10.2 mg/dL | | Total protein | 6.3 to 8.2 g/dL | | Albumin | 3.5 to 5.0 g/dL | | Total bilirubin | 0.1 to 1.2 mg/dL | | ALP | 44 to 147 U/L | | AST | 10 to 40 U/L | | ALT | 7 to 56 U/L |

Reference ranges vary by analyzer, reagent lot, and patient sex or age. Always interpret results against the specific laboratory's reference interval printed on the report. KDIGO 2024 CKD guidelines note that eGFR should be confirmed on two separate occasions at least 90 days apart before a CKD diagnosis is assigned.

Why Drug Interference Matters Clinically

A drug can shift a CMP value through three distinct mechanisms. First, true pharmacological effect: the drug genuinely changes the biology (thiazides deplete potassium). Second, analytical interference: the drug or its metabolite cross-reacts with the assay reagent and produces a spurious number. Third, pre-analytical artifact: the drug changes specimen handling behavior (hemolysis, protein binding). Distinguishing these mechanisms determines whether the clinical response is to adjust the drug, repeat the test, or investigate organ pathology. The National Academy of Clinical Biochemistry published a landmark guideline distinguishing analytical from biological drug interference in clinical chemistry panels.

Drugs That Distort Serum Glucose

Corticosteroids

Prednisone, dexamethasone, methylprednisolone, and hydrocortisone all raise fasting serum glucose through gluconeogenesis and insulin resistance. The magnitude is dose-dependent. Prednisone 40 mg/day in non-diabetic adults raises postprandial glucose by an average of 80 to 100 mg/dL and fasting glucose by 20 to 40 mg/dL. The ADA Standards of Medical Care in Diabetes 2024 classifies steroid-induced hyperglycemia as a distinct management category requiring separate monitoring protocols.

Glucose elevations typically peak 4 to 8 hours after the morning steroid dose. A fasting CMP drawn before the dose may appear deceptively normal in a patient with significant midday steroid hyperglycemia.

Thiazide and Loop Diuretics

Hydrochlorothiazide and chlorthalidone impair pancreatic beta-cell insulin secretion by reducing intracellular potassium. The ALLHAT trial (N=33,357) found that chlorthalidone-treated patients had a 12.6% incidence of new-onset diabetes vs. 8.1% in the amlodipine arm over 4 to 8 years of follow-up. ALLHAT data published in JAMA remain the most-cited evidence for diuretic-induced glucose elevation.

Furosemide produces smaller glucose effects than thiazides, but at doses above 80 mg/day the effect becomes clinically measurable. A random glucose on a CMP in a hypertensive patient on hydrochlorothiazide 25 mg/day should always be interpreted with this context.

Antipsychotics and Other Metabolic Disruptors

Second-generation antipsychotics, particularly olanzapine and clozapine, raise fasting glucose independent of weight gain. A meta-analysis in JAMA Psychiatry found olanzapine increased fasting glucose by a mean of 4.9 mg/dL vs. Placebo across 14 randomized trials. Tacrolimus, a calcineurin inhibitor used after organ transplantation, inhibits insulin secretion directly and causes new-onset diabetes after transplant (NODAT) in 10 to 20% of recipients. Transplantation Society guidelines recommend fasting glucose monitoring every 3 months for the first year post-transplant.

Beta-blockers (especially non-selective agents like propranolol) blunt the adrenergic symptoms of hypoglycemia and can mask a low glucose reading's clinical context, though they do not directly alter the measured glucose value on the CMP.

Drugs That Distort Creatinine and eGFR

Trimethoprim and Cimetidine: Secretion Blockers

Trimethoprim (the antibiotic component of trimethoprim-sulfamethoxazole) competitively inhibits tubular secretion of creatinine without affecting actual glomerular filtration rate. The result is a predictable rise in serum creatinine of 0.1 to 0.4 mg/dL at standard doses (160 mg twice daily). A study in Annals of Internal Medicine demonstrated this effect clearly, showing that cimetidine (an H2-blocker) produces an identical mechanism: creatinine rises while true GFR is unchanged.

This matters most in patients being monitored for CKD progression. A creatinine bump from a 10-day course of TMP-SMX should not be attributed to a nephrology emergency without checking medication history first.

NSAIDs and COX-2 Inhibitors

Ibuprofen, naproxen, indomethacin, and celecoxib reduce renal prostaglandin synthesis, causing afferent arteriolar constriction and a genuine but reversible drop in GFR. In healthy adults this effect is minor. In patients with baseline CKD, heart failure, or cirrhosis, serum creatinine may rise 0.3 to 0.8 mg/dL within 3 to 7 days of NSAID initiation. KDIGO 2024 guidelines advise against chronic NSAID use in patients with eGFR <60 mL/min/1.73 m².

Unlike trimethoprim's purely analytical interference, NSAID-related creatinine elevation is a real physiological effect that reverses when the drug is stopped.

Creatine Supplements and High-Protein Diets

Oral creatine monohydrate supplementation raises serum creatinine because creatine is spontaneously converted to creatinine in a non-enzymatic reaction. A crossover study in Journal of the American Society of Nephrology showed that 20 g/day of creatine for 5 days raised serum creatinine by a mean of 0.22 mg/dL without any change in inulin clearance (true GFR). Patients who take creatine for athletic performance should stop supplementation at least 72 hours before a CMP intended to assess kidney function.

High red-meat intake on the day before a CMP can similarly raise creatinine by 0.1 to 0.2 mg/dL due to dietary creatine load.

Drugs That Distort Electrolytes

Potassium: Drugs That Raise It

ACE inhibitors (lisinopril, enalapril) and angiotensin receptor blockers (losartan, valsartan) reduce aldosterone-mediated potassium excretion. Potassium-sparing diuretics (spironolactone, eplerenone, amiloride) act directly on the collecting duct to retain potassium. In the RALES trial (N=1,663), spironolactone 25 to 50 mg/day raised potassium by a mean of 0.3 mEq/L; results published in NEJM prompted routine potassium monitoring at 1, 3, and 6 months after initiation.

Trimethoprim-sulfamethoxazole also blocks sodium channels in the collecting duct, behaving like amiloride and raising potassium by 0.5 to 1.0 mEq/L in susceptible patients.

Potassium: Drugs That Lower It

Thiazide diuretics (hydrochlorothiazide, chlorthalidone) and loop diuretics (furosemide, bumetanide) cause urinary potassium wasting. Furosemide 40 mg/day lowers serum potassium by 0.3 to 0.5 mEq/L on average; the magnitude is proportional to dose and sodium intake. High-dose corticosteroids enhance distal tubular sodium reabsorption and secondary potassium excretion. Insulin drives potassium intracellularly and lowers serum potassium acutely by 0.5 to 1.0 mEq/L at therapeutic doses. A review in the Clinical Journal of the American Society of Nephrology summarizes these mechanisms comprehensively.

Sodium: Drugs That Shift It

SIADH (syndrome of inappropriate ADH secretion) is the most common drug-induced cause of hyponatremia. SSRIs, carbamazepine, oxcarbazepine, cyclophosphamide, and vincristine all stimulate ADH or potentiate its renal effect. Oxcarbazepine causes clinically significant hyponatremia (sodium <135 mEq/L) in approximately 25% of patients. A prospective cohort in Neurology found a mean sodium decrease of 4.6 mEq/L at standard therapeutic doses.

Lithium, conversely, causes nephrogenic diabetes insipidus and hypernatremia in chronic users by blocking aquaporin-2 upregulation.

Bicarbonate and Acid-Base

Topiramate and zonisamide inhibit carbonic anhydrase, causing a non-anion-gap metabolic acidosis and a low CO2 on the CMP. The effect is dose-dependent; topiramate 200 mg/day lowers serum bicarbonate by approximately 4 mEq/L in adults. FDA prescribing information for topiramate includes a specific warning about metabolic acidosis with monitoring recommendations.

Loop and thiazide diuretics increase bicarbonate (metabolic alkalosis) through hydrogen ion and chloride loss. A furosemide-treated patient may show CO2 of 30 to 33 mEq/L without any respiratory pathology.

Calcium: Drugs That Raise or Lower It

Thiazide diuretics reduce renal calcium excretion and can raise serum calcium by 0.5 to 1.0 mg/dL with chronic use. Excessive vitamin D supplementation raises calcium through intestinal absorption. Lithium raises calcium by shifting the set-point for PTH secretion; hypercalcemia occurs in 10 to 15% of long-term lithium users. A case series in NEJM documented PTH-dependent hypercalcemia reversal after lithium discontinuation.

Loop diuretics lower calcium through urinary wasting and are occasionally used therapeutically in hypercalcemia of malignancy for this reason. Bisphosphonates (alendronate, zoledronic acid) suppress bone resorption and can cause hypocalcemia, particularly in patients with vitamin D deficiency at baseline.

Drugs That Distort Liver Enzymes (AST, ALT, ALP, Bilirubin)

Statins

Statin-induced transaminase elevation is one of the most over-investigated findings in clinical practice. Clinically significant AST or ALT elevations (greater than 3 times the upper limit of normal) occur in fewer than 1% of statin users at standard doses. A pooled analysis of 49 trials cited in JAMA Internal Medicine found the absolute rate of significant transaminase elevation was 0.5% with atorvastatin 80 mg/day vs. 0.1% with placebo. Mild transaminase elevations (1 to 3× ULN) are common, transient, and do not predict liver injury.

Routine liver enzyme monitoring is no longer recommended for statin users without symptoms, per 2022 ACC/AHA guidelines.

Acetaminophen and Dose-Dependent Hepatotoxicity

Acetaminophen produces dose-dependent hepatocellular injury through N-acetyl-p-benzoquinone imine (NAPQI) accumulation. At doses above 3 g/day in chronic alcohol users or patients with pre-existing liver disease, AST and ALT can rise dramatically. A Hepatology review notes that acetaminophen is responsible for approximately 46% of all acute liver failure cases in the United States, with a mean peak ALT exceeding 3,000 U/L in severe cases.

At therapeutic doses in healthy adults, acetaminophen does not produce clinically relevant transaminase elevation on routine CMPs.

Valproate, Azathioprine, and Methotrexate

Valproate raises AST and ALT in 5 to 10% of patients and can cause a rare but severe mitochondrial hepatotoxicity, particularly in children under age 2 with metabolic disorders. FDA label guidance for valproate requires liver function monitoring before therapy and at frequent intervals during the first 6 months.

Azathioprine causes a distinct hepatocanalicular cholestatic pattern with ALP and GGT elevation more prominent than AST/ALT. Methotrexate at doses used for rheumatoid arthritis (7.5 to 25 mg/week) raises ALT in 15 to 50% of patients over time; cumulative hepatotoxicity correlates with total lifetime dose exceeding 1.5 g. ACR guidelines recommend monitoring ALT every 4 to 8 weeks during methotrexate therapy.

Isoniazid and Rifampin

Both first-line antituberculosis drugs raise transaminases. Isoniazid causes asymptomatic ALT elevation in 10 to 20% of patients; clinically significant hepatitis requiring drug discontinuation occurs in 0.5 to 2% of patients. Rifampin elevates bilirubin (by competing for hepatic bilirubin uptake transport) and can cause a jaundiced-appearing CMP without true liver injury. A prospective study in Lancet Infectious Diseases found the combination of isoniazid plus rifampin had an additive hepatotoxic effect, particularly in patients over age 35.

Drugs That Distort BUN and the BUN:Creatinine Ratio

Corticosteroids and High-Dose Tetracyclines

Prednisone and other glucocorticoids increase protein catabolism, raising BUN without any reduction in GFR. A BUN of 30 mg/dL in a patient taking prednisone 40 mg/day with a normal creatinine of 0.9 mg/dL produces a BUN:creatinine ratio of 33:1. That ratio normally signals prerenal azotemia (dehydration) or gastrointestinal bleeding, but in this case it reflects steroid-driven protein turnover. A clinical chemistry reference in Annals of Internal Medicine clarified that glucocorticoid-induced BUN elevation is a direct pharmacological effect on hepatic ureagenesis.

High-dose tetracyclines (doxycycline above 200 mg/day) also raise BUN through an anti-anabolic effect on protein metabolism; this mechanism is why tetracyclines are avoided in patients with pre-existing renal impairment.

GLP-1 Receptor Agonists and SGLT-2 Inhibitors

GLP-1 receptor agonists (semaglutide, tirzepatide) cause volume depletion at treatment initiation through nausea and reduced oral intake. Mild BUN elevation (BUN 22 to 28 mg/dL) with stable creatinine during the first 4 to 8 weeks of GLP-1 therapy is typically a volume effect rather than true renal injury. The SUSTAIN-6 trial (N=3,297) found semaglutide 0.5 and 1.0 mg did not worsen renal function; NEJM published results showing a non-significant trend toward lower urinary albumin-to-creatinine ratio.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) cause a reproducible initial creatinine rise of 0.1 to 0.2 mg/dL through hemodynamic reduction in GFR. This is expected, does not progress, and actually predicts long-term renoprotection. The CREDENCE trial (N=4,401) showed canagliflozin reduced the composite of ESRD, doubling of creatinine, and renal/CV death by 30% despite the initial creatinine bump.

Drugs That Distort Total Protein and Albumin

Anabolic Steroids and Testosterone

Anabolic steroids and supraphysiologic testosterone increase hepatic protein synthesis, raising total protein and sometimes albumin modestly. More clinically relevant is the effect on the albumin-to-globulin ratio. Testosterone cypionate 200 mg every 2 weeks modestly raises total protein in hypogonadal men, an effect documented in Endocrine Society clinical practice guidelines on testosterone therapy through changes in hepatic synthetic function.

Drugs That Lower Albumin

Albumin is a negative acute-phase reactant: any drug producing systemic inflammation will lower it. Interleukin-2 (used in metastatic melanoma) drops albumin to 2.5 to 3.0 g/dL within days through capillary leak syndrome. Chemotherapy agents broadly lower albumin through malnutrition and inflammation. Valproate displaces albumin-bound drugs through competitive protein binding but does not lower the measured albumin value on the CMP. A pharmacokinetics review in Clinical Pharmacokinetics details protein-binding displacement interactions for anticonvulsants.

A Framework for Interpreting a Distorted CMP

When a CMP returns with an unexpected abnormality, applying a four-step sequence prevents unnecessary workup.

Step 1. List every drug, supplement, and over-the-counter agent taken in the 72 hours before the draw. Include creatine supplements, NSAIDs, and any newly started antibiotic.

Step 2. Match the abnormal analyte to the known pharmacological effect of each agent. A single drug (TMP-SMX) explaining both a creatinine bump and a potassium rise is a coherent drug-effect narrative, not organ failure.

Step 3. Assess magnitude. Drug-effect distortions are usually small (0.1 to 0.5 mg/dL for creatinine, 5 to 15 mg/dL for glucose, 0.3 to 0.5 mEq/L for potassium). Values outside these ranges warrant independent investigation.

Step 4. Repeat the CMP after the offending drug is held for 48 to 72 hours. Normalization on repeat confirms interference. Persistence requires pathological explanation.

As the American Association for Clinical Chemistry has noted, "Drug interference with laboratory tests remains one of the most underrecognized sources of diagnostic error in clinical medicine."

How to Raise or Lower Specific CMP Values Through Drug Adjustments

Glucose can be lowered on a CMP by stopping or reducing corticosteroid dose, switching from hydrochlorothiazide to a calcium-channel blocker in a hypertensive patient with prediabetes, or adding a GLP-1 receptor agonist. Creatinine can be normalized by stopping TMP-SMX or an NSAID and repeating the CMP in 5 to 7 days. Potassium can be raised by starting spironolactone or holding a loop diuretic. Potassium can be lowered by reducing an ACE inhibitor dose or stopping trimethoprim.

Liver enzymes can be lowered by discontinuing the offending drug: AST and ALT typically return to baseline within 4 to 8 weeks after stopping a statin, within 2 to 6 weeks after stopping methotrexate for isolated enzyme elevation, and within 2 to 3 months after stopping valproate if injury is caught early. AASLD Practice Guidance on drug-induced liver injury defines "recovery" as transaminase values returning to within 2× ULN after drug cessation.

Serum bicarbonate can be raised by stopping topiramate or zonisamide; it typically normalizes within 2 weeks. A pharmacology review in Clinical Neuropharmacology documented full bicarbonate recovery in 14 of 14 patients within 21 days of topiramate discontinuation.

Calcium can be lowered on a CMP by stopping excess vitamin D or calcium supplementation (serum calcium normalizes in 1 to 3 weeks) or, in lithium-associated hypercalcemia, by reducing lithium to the lowest therapeutic dose while checking PTH levels.